Visit Quintiles in booth #1.E06 at this year’s ERS International Congress, and learn how we can improve your probability of success.
Through our early clinical expertise and strong commercial knowledge, we can enhance predictability of outcomes in respiratory drug development.
This year, Graham Clarke, Senior Director and Head of the Respiratory and Inflammation Unit, Early Clinical Development at Quintiles, will be presenting during a session with colleagues from AstraZeneca. We hope you are able to attend this exciting session!
Title: AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans
Date and Time: 27-09-2015 from 10:45 to 12:45
Location: Room 2.1
Posters (Displayed at Booth):
• A global survey conducted to determine current management of asthma (Presented at EACCI 2014)
• Discordant intra-individual upper and lower airway responses following simultaneous nasal and bronchial allergen challenges (Presented at ERS 2014)
• Sputum processing methods in airway disease: Which is best? (Presented at ERS 2014)
• The nose as a research tool: Intra-subject variability in nasal sampling (Presented at ERS 2011)
To schedule a meeting to connect with a Quintiles expert, click here. We look forward to seeing you in Amsterdam!